1. Generics Bulletin
  2. >>Business

Piramal To Plant A Flag In North America

Agreement Reached For Oral Solids Plant In Pennsylvania

 
• By Dean Rudge

Indian contract development and manufacturing organization Piramal Pharma Solutions is to bolster its manufacturing capabilities after agreeing to acquire a site from US-based G&W Laboratories, with plans to offer high-potency drug manufacturing capabilities in the future.

Handshake
Piramal and G&W have shaken hands on a deal for a US manufacturing site • Source: Shutterstock

Piramal Pharma Solutions is to have “solid oral dose capabilities on three continents,” after agreeing to acquire G&W Laboratories’ US solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania, to add to existing manufacturing in the UK and India.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.